Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)

Core Viewpoint - A class action securities lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud that affected investors between November 2, 2023, and October 30, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Regeneron made false statements and concealed payments made to distributors to cover credit card fees, which misled investors about the pricing and sales of Eylea [2]. - It is alleged that these payments allowed Regeneron to offer price concessions that lowered Eylea's selling price, misleadingly boosting reported sales figures [2]. - The complaint also states that Regeneron failed to report these payments as price concessions, resulting in an overstatement of the Average Selling Price (ASP) reported to federal agencies, thus violating the False Claims Act [2]. Group 2: Investor Actions - Investors who suffered losses during the specified timeframe have until March 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation model [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].